Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1029

1.

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC.

Cells. 2019 Nov 26;8(12). pii: E1522. doi: 10.3390/cells8121522. Review.

2.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group.

Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072.

PMID:
31735560
3.

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV.

Blood Adv. 2019 Nov 12;3(21):3248-3260. doi: 10.1182/bloodadvances.2019000703.

4.

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.

Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS.

Clin Cancer Res. 2019 Oct 31. doi: 10.1158/1078-0432.CCR-19-0647. [Epub ahead of print]

PMID:
31672767
5.

The impact of response kinetics for multiple myeloma in the era of novel agents.

Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, Yi S, Xu Y, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Wang J, Cheng T, Zhan F, Tai YT, Yuan C, Du X, Qiu L, Anderson KC, An G.

Blood Adv. 2019 Oct 8;3(19):2895-2904. doi: 10.1182/bloodadvances.2019000432.

6.

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.

Ray A, Song Y, Du T, Tai YT, Chauhan D, Anderson KC.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0558-x. [Epub ahead of print]

PMID:
31462737
7.

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG.

Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4.

PMID:
31456261
8.

Insights into the management of older patients with multiple myeloma.

Anderson KC.

Clin Adv Hematol Oncol. 2019 Jul;17(7):390-392. No abstract available.

PMID:
31449504
9.

Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT, Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC, Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N, Campbell PJ.

Nat Commun. 2019 Aug 23;10(1):3835. doi: 10.1038/s41467-019-11680-1.

10.

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Ray A, Song Y, Chauhan D, Anderson KC.

Blood Cancer J. 2019 Aug 12;9(8):64. doi: 10.1038/s41408-019-0224-6. No abstract available.

11.

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA.

Future Oncol. 2019 Oct;15(28):3267-3281. doi: 10.2217/fon-2019-0368. Epub 2019 Aug 9.

12.

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia.

Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP.

Clin Cancer Res. 2019 Aug 1;25(15):4860. doi: 10.1158/1078-0432.CCR-19-2051. No abstract available.

PMID:
31371310
13.

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Tai YT, Anderson KC.

Expert Opin Biol Ther. 2019 Nov;19(11):1143-1156. doi: 10.1080/14712598.2019.1641196. Epub 2019 Jul 11.

PMID:
31277554
14.

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0498-5. [Epub ahead of print]

PMID:
31182781
15.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
16.

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.

Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC, O'Gorman P, Bianchi G.

Leukemia. 2019 May 29. doi: 10.1038/s41375-019-0493-x. [Epub ahead of print]

17.

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. No abstract available.

PMID:
31043386
18.

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.

Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D.

Leukemia. 2019 Nov;33(11):2685-2694. doi: 10.1038/s41375-019-0467-z. Epub 2019 Apr 8.

19.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380. doi: 10.1016/j.clml.2019.02.006. Epub 2019 Feb 21.

PMID:
30930134
20.

Deciphering the chronology of copy number alterations in Multiple Myeloma.

Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK.

Blood Cancer J. 2019 Mar 26;9(4):39. doi: 10.1038/s41408-019-0199-3.

21.
22.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
23.

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA.

Am J Hematol. 2019 May;94(5):E146-E149. doi: 10.1002/ajh.25441. Epub 2019 Mar 6. No abstract available.

PMID:
30773670
24.

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Cho SF, Anderson KC, Tai YT.

Ann Transl Med. 2018 Dec;6(Suppl 2):S93. doi: 10.21037/atm.2018.11.14. No abstract available.

25.

Body Composition Is Associated With Physical Performance in Individuals With Knee Osteoarthritis.

Davis HC, Blue MNM, Hirsch KR, Luc-Harkey BA, Anderson KC, Smith-Ryan AE, Pietrosimone B.

J Clin Rheumatol. 2019 Feb 1. doi: 10.1097/RHU.0000000000000967. [Epub ahead of print]

PMID:
30724754
26.

The NIH Blueprint for Neuroscience Research Seeks Community Input on Future Neuroscience Investments.

Mott MC, Austin CP, Bianchi DW, Cashion AK, Gordon JA, Heemskerk JE, Hodes RJ, Koob GF, Riley WT, Sieving PA, Shurtleff D, Somerman MJ, Volkow ND, Anderson KC, Owens DF, Koroshetz WJ.

J Neurosci. 2019 Jan 30;39(5):774-775. doi: 10.1523/JNEUROSCI.2742-18.2018. No abstract available.

27.

Contribution of Inhibition of Protein Catabolism in Myeloma.

Bianchi G, Anderson KC.

Cancer J. 2019 Jan/Feb;25(1):11-18. doi: 10.1097/PPO.0000000000000349.

PMID:
30694855
28.

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.

Guang MHZ, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O'Gorman P, McCann A.

Cancers (Basel). 2019 Jan 9;11(1). pii: E66. doi: 10.3390/cancers11010066. Review.

29.

PRMT5 inhibitors on the (myeloma) road.

Gulla A, Hideshima T, Anderson KC.

Oncotarget. 2018 Nov 30;9(94):36646-36647. doi: 10.18632/oncotarget.26392. eCollection 2018 Nov 30. No abstract available.

30.

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC.

Cell Rep. 2018 Dec 26;25(13):3693-3705.e6. doi: 10.1016/j.celrep.2018.12.016.

31.

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Wildes TM, Anderson KC.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):88-96. doi: 10.1182/asheducation-2018.1.88. Review.

32.

The power of proteasome inhibition in multiple myeloma.

Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG.

Expert Rev Proteomics. 2018 Dec;15(12):1033-1052. doi: 10.1080/14789450.2018.1543595. Epub 2018 Nov 14. Review.

PMID:
30427223
33.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

34.

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP.

Blood Adv. 2018 Nov 13;2(21):2937-2946. doi: 10.1182/bloodadvances.2018022962.

35.

The effects of nutrient timing on training adaptations in resistance-trained females.

Pihoker AA, Peterjohn AM, Trexler ET, Hirsch KR, Blue MNM, Anderson KC, Ryan ED, Smith-Ryan AE.

J Sci Med Sport. 2019 Apr;22(4):472-477. doi: 10.1016/j.jsams.2018.09.236. Epub 2018 Oct 10.

PMID:
30366741
36.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315237
37.

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM.

Clin Cancer Res. 2019 Jan 15;25(2):478-486. doi: 10.1158/1078-0432.CCR-18-1325. Epub 2018 Oct 2.

PMID:
30279233
38.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

39.

A transcriptomic investigation of appetite-regulation and digestive processes in giant grouper Epinephelus lanceolatus during early larval development.

Anderson KC, Knuckey R, Cánepa M, Elizur A.

J Fish Biol. 2018 Oct;93(4):694-710. doi: 10.1111/jfb.13798.

PMID:
30232812
40.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC.

Leukemia. 2018 Oct;32(10):2305. doi: 10.1038/s41375-018-0235-5.

41.

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.

Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M.

Clin Cancer Res. 2019 Jan 1;25(1):369-377. doi: 10.1158/1078-0432.CCR-18-1776. Epub 2018 Sep 11.

PMID:
30206161
42.

The biological significance of histone modifiers in multiple myeloma: clinical applications.

Ohguchi H, Hideshima T, Anderson KC.

Blood Cancer J. 2018 Aug 22;8(9):83. doi: 10.1038/s41408-018-0119-y. Review.

43.

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG.

Clin Adv Hematol Oncol. 2018 Aug;16(8):564-574. Review.

PMID:
30148829
44.

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Tai YT, Cho SF, Anderson KC.

Front Immunol. 2018 Aug 10;9:1822. doi: 10.3389/fimmu.2018.01822. eCollection 2018. Review.

45.

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Cho SF, Anderson KC, Tai YT.

Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018. Review.

46.

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC.

Leukemia. 2019 Feb;33(2):426-438. doi: 10.1038/s41375-018-0242-6. Epub 2018 Aug 22.

47.

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.

Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA.

Clin Cancer Res. 2018 Dec 15;24(24):6570-6582. doi: 10.1158/1078-0432.CCR-18-1300. Epub 2018 Aug 21.

48.

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.

Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, Peng Z, Tai YT, Hideshima T, Anderson KC, Cang Y.

Leukemia. 2019 Jan;33(1):171-180. doi: 10.1038/s41375-018-0205-y. Epub 2018 Jul 19.

49.

Promise of Immune Therapies in Multiple Myeloma.

Anderson KC.

J Oncol Pract. 2018 Jul;14(7):411-413. doi: 10.1200/JOP.18.00311. No abstract available.

50.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.

Supplemental Content

Loading ...
Support Center